Estrella Immunopharma Inc
Research Estrella Immunopharma Inc (ESLA) on Bullrun: market cap USD 31.54M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerESLA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 31.54M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 13.25M
- Free cash flow-USD 8.02M
Valuation Snapshot
latest market cap is USD 31.54M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 13.06M | -USD 1.79M | n/a | -0.35 | USD 1.38M | n/a | -USD 10.37M |
| FY2024 | n/a | -USD 7.31M | n/a | n/a | -0.27 | USD 4.17M | n/a | USD 4.27M |
| FY2023 | n/a | -USD 11.11M | n/a | n/a | -36.35 | USD 2.48M | USD 300.00K | -USD 11.74M |
| FY2022 | n/a | -USD 996.10K | n/a | n/a | -34.49 | USD 40.80K | USD 50.00K | -USD 6.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 31.54M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 59.23M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 43.43M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 39.07M | n/a | n/a | n/a |
About Estrella Immunopharma Inc
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Estrella Immunopharma Inc's market cap?
Estrella Immunopharma Inc's market capitalization is USD 31.54M.
What does Estrella Immunopharma Inc do?
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.